Logo Logo Reversed

Cardiovascular Disease

Battling the top cause of death worldwide Comprehensive testing can support care for patients before and after adverse cardiac events

According to the World Health Organization, cardiovascular diseases are the number one cause of death globally, with more people dying from cardiovascular diseases each year than any other cause.1 Since hereditary and lifestyle factors can affect a patient's risk of experiencing cardiovascular disease, medical monitoring and management of patient conditions and behaviors can last for years. 

Cardiovascular disease management has financial impacts. The CDC Foundation has reported that about one in every six U.S. healthcare dollars is spent on cardiovascular disease.2 By 2030, annual direct medical costs associated with cardiovascular diseases are projected to rise to more than $818 billion.3

Clinical laboratories can support care for patients experiencing, or at risk for, cardiovascular disease. Comprehensive testing, in combination with medical monitoring and treatment, can help with cardiovascular disease diagnosis, management and therapies.

Critical tests for acute care When every minute matters, speed and accuracy of results are paramount

Successful management of cardiovascular disease means avoiding adverse events. Successful treatment of acute coronary syndrome (ACS) requires making the right decisions quickly.

Below are just a few things that are essential to patient survival and care:

  • Identifying important risk factors
  • Making a fast diagnosis and prognosis
  • Monitoring therapeutic success
  • Estimating the individual's cardiovascular risk

The speed and accuracy of the information your laboratory delivers are critical to improving patient outcomes and reducing the cost of care. 

Support Patients Experiencing, or at Risk for, Cardiovascular Disease Our comprehensive cardiac menu provides the tests you need to support informed clinical decision making

For Access 2 and DxI Series Analyzers

  • AccuTnI+3 (Troponin I)
  • Access hsTnI
  • CK-MB (Creatine Kinase MB)
  • Digoxin
  • Myoglobin
  • Triage BNP*

For AU and IMMAGE Series Analyzers

  • Apolipoprotein A-1
  • Apolipoprotein B
  • C-Reactive Protein, High Sensitivity
  • CK 
  • CK-MB
  • HDL
  • Homocysteine
  • LDL
  • Lipoprotein(a)
  • TRIG
     

Access hsTnI empowers earlier treatment in acute-care settings  Confidently report accurate results with the first true high-sensitivity troponin I assay cleared by the U.S. FDA

When a patient comes to the emergency department with a suspected ACS, the speed and accuracy of the diagnostics have a critical impact on outcome and cost of care. High-sensitivity troponin tests support more rapid decision making, which can help detect at-risk patients sooner4 and send acute myocardial infarction (AMI)-negative patients home faster, reducing triage time by hours.5 
 
New and improved tests for AMI are on the horizon. Learn how high-sensitivity troponin assays may lead to earlier and more effective treatment for patients.
hsTnI Assay

Access hsTnI

Access hsTnI enables clinicians to provide efficiency improvements in cardiac patient management. By detecting troponin I—a protein that is released into the circulation during MI—Access hsTnI gives clinicians important insight into life-threatening cardiac conditions in patients presenting with chest pain, fast. 

View details

Cutting ED triage time in half Access AccuTnI+3 provides fast, accurate information for better patient care

The clinical utility of cardiac troponin continues to evolve. Since the introduction of the first diagnostic cardiac troponin test nearly two decades ago, assay improvements have been quickly followed by changes in utility due to the unique sensitivity and specificity of cardiac troponin for cardiac injury.  

As the analytical performance of cardiac troponin continues to improve, better precision around the clinical decision point is enabling earlier rule-in and rule-out for non-ST-elevation AMI. Check out these resources to find out more about the cardiac troponin assay advantage:

Total laboratory solutions for cardiac care Build your laboratory's cardiac capabilities on a broad foundation

Helping physicians diagnose cardiac disease and monitor the treatment of their patients is your challenge—and to meet it, your laboratory needs comprehensive diagnostic tools. 

Our total laboratory solutions deliver accurate information for medical research breakthroughs, clinical trials and laboratory diagnostics. Our partnership with you extends far beyond our products. With proven expertise in analyzing laboratory test processes, we collaborate with you to understand your requirements and create flexible solutions that meet your evolving needs.

Let us help you enhance your laboratory to support your patients' cardiovascular health management needs today and tomorrow. Contact us to get started.

1World Health Organization. "Cardiovascular diseases (CVDs) Fact Sheet." May 2017. http://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed on 20 June 2018.

2CDC Foundation. "Heart Disease And Stroke Cost America Nearly $1 Billion A Day In Medical Costs, Lost Productivity." April 2015. https://www.cdcfoundation.org/pr/2015/heart-disease-and-stroke-cost-america-nearly-1-billion-day-medical-costs-lost-productivity. Last accessed on 20 June 2018.

3Ibid.

4Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012; 33: 2252-7. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol, 2013; 61:1753-8.

5Storrow, AB et al. Diagnostic Performance of Cardiac Troponin I For Early Rule-in and Rule-out of Acute Myocardial Infarction: Results of a Prospective Multicenter Trial. Clinical Biochemistry, 2015; 48:254-259.

*Available exclusively from Alere or its authorized distributors for use on Beckman Coulter immunoassay systems.

Alere and Triage are trademarks of the Alere group of companies.